Expression analysis of microRNA as prognostic biomarkers in colorectal cancer

Jie Yang; Dongling Ma; Andrew Fesler; Haiyan Zhai; Apisri Leamniramit; Wenzhe Li; Song Wu; Jingfang Ju

doi:10.18632/oncotarget.14175

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression analysis of microRNA as prognostic biomarkers in colorectal cancer

Jie Yang _, Dongling Ma, Andrew Fesler, Haiyan Zhai, Apisri Leamniramit, Wenzhe Li, Song Wu and Jingfang Ju

PDF | HTML | How to cite

Oncotarget. 2017; 8:52403-52412. https://doi.org/10.18632/oncotarget.14175

Metrics: PDF 2167 views | HTML 2787 views | ?

Abstract

Jie Yang4,*, Dongling Ma2,*, Andrew Fesler1,*, Haiyan Zhai1, Apisri Leamniramit2, Wenzhe Li2, Song Wu3 and Jingfang Ju1

1Translational Research Laboratory, Department of Pathology, Stony Brook University, Stony Brook, NY 11794, USA

2The NMS Laboratory, Stony Brook University, Stony Brook, NY, 11794, USA

3Department of Applied Mathematics, Stony Brook University, Stony Brook, NY, 11794, USA

4Department of Family, Population and Preventive Medicine, Stony Brook, NY 11794, USA

*These authors have contributed equally to this work

Correspondence to:

Jingfang Ju, email: [email protected]

Keywords: colorectal cancer, prognosis, microRNA, chemotherapy

Received: September 08, 2016 Accepted: November 19, 2016 Published: December 26, 2016

ABSTRACT

microRNA (miRNA) based biomarkers have unique advantages due to their critical regulatory function, superior stability, and relatively small number compared to mRNAs. A number of miRNAs play key roles in colon cancer stem cell chemoresistance and have clinical potential as prognostic biomarkers. The purpose of this study is to systematically validate the prognostic potential of miRNAs in colorectal cancer. In this study, we validated the prognostic potential of a panel of miRNAs using 205 stage II, III, and IV colorectal cancer specimens by qRT-PCR analysis. We cross validated our results using The Cancer Genome Atlas (TCGA) database. Many of the miRNAs we investigated have been functionally validated to be important in contributing to chemoresistance to 5-fluorouracil (5-FU) based chemotherapy. We determined that miR-16 is the most consistent miRNA for expression normalization in colorectal cancer. We have validated several miRNAs (miR-15b, miR-215, miR-145, miR-192, let-7g) that are significantly associated with progression free survival (PFS) and/or overall survival (OS) of colorectal cancer patients independent of tumor stage and age at diagnosis. These 5 miRNAs are significantly associated with OS of colorectal cancer even after tumor location (left side vs. right side) is adjusted for. Furthermore, the prognostic value of let-7g for overall survival was independently validated using the RNA-Seq results from TCGA colorectal cancer database. These results, taken together, establish a solid foundation towards miRNA based precision management of colorectal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14175

Publication Alerts

Research Papers:

Expression analysis of microRNA as prognostic biomarkers in colorectal cancer

Abstract